Cyclic peptides have been getting more and more attention in drug discovery lately. They hold their shape well, resist breakdown in the body, and bind tightly to targets – all good things. But finding and making high-quality cyclic peptides from messy natural sources like protein hydrolysates? A recent paper in Antioxidants showed a pretty clever workaround. The team used bioinformatics, enzymatic digestion, and molecular docking to fish out several new antioxidant cyclic peptides from corn gluten meal. Here we break down their approach and look at how professional purification, characterization, and drug development services can help push such active cyclic peptides from the lab bench toward early preclinical testing.
Cyclic peptides exhibit significant potential in functional foods and drug development due to their superior conformational stability and in vivo metabolic stability compared to linear peptides. Traditionally, discovering cyclic peptides from natural products or protein hydrolysates relied on trial and error, a lengthy and inefficient process. Particularly when utilizing food industry byproducts such as corn gluten meal (CGM), the core challenge has been how to precisely release and identify target cyclic peptides from complex protein mixtures.
CGM is rich in hydrophobic amino acids (such as Pro, Leu, Ala), which are ideal structural units for cyclic peptide formation. However, traditional methods struggle to predict which enzyme or enzyme combination can most effectively release antioxidant cyclic peptides. The research team led by Liu Hongcheng targeted this bottleneck precisely, aiming to develop a more efficient discovery strategy.
This study unveils a new direction for cyclic peptide discovery: bioinformatics-assisted precision enzymatic design. Through in silico enzymatic digestion, researchers can predict the optimal enzyme combination before experimentation, dramatically improving discovery efficiency and target product yield. This predict-first, validate-later model represents a shift in cyclic peptide research from experience-driven to data-driven approaches.
Liu Hongcheng and colleagues not only successfully discovered 11 novel antioxidant cyclic peptides but, more importantly, their workflow provides a replicable and highly efficient paradigm for the entire field.
The research team first utilized the BIOPEP database to perform in silico enzymatic digestion of the major proteins in CGM. They compared single and combined enzyme treatments involving three common proteases. Results indicated that the "papain + subtilisin" combination released the highest number of antioxidant peptide fragments and cyclization-prone precursors during simulated hydrolysis. This prediction guided subsequent wet-lab experiments, avoiding blind trials and minimizing time and cost.
Subsequent enzymatic experiments validated the prediction's accuracy. The hydrolysate from this combination not only achieved the highest cyclic peptide yield but also exhibited superior DPPH, ABTS, and hydroxyl radical scavenging rates compared to other treatments.
TLC (A) and antioxidant activity & cyclic peptide yield (B) of CGM hydrolysates from different enzyme combos1,4
Using TLC, silica gel column chromatography, and semi-preparative RP-HPLC, the research team successfully isolated highly active sub-fractions from the hydrolysate.
(A) Cyclic peptide yield, (B) DPPH, (C) ABTS, and (D) hydroxyl radical scavenging rates of the fractions separated by silica column2,4
Following silica gel column separation, as illustrated in Figure 3, fractions F1 and F2 exhibited the highest cyclic peptide yields (approximately 92%), while fraction F3 displayed the strongest free radical scavenging activity (DPPH scavenging rate of 84.82 ± 1.77%). Subsequently, F1 and F2 underwent further fine separation using semi-preparative RP-HPLC.
Separation profiles of Fl (A) and F2 (B) on semi-preparative RP-HPLC chromatography3,4
Ultimately, using UPLC-MS/MS and Orbitrap-MS/MS technologies, they precisely identified the amino acid sequences of 11 cyclic peptides, giving them a clear link between structure and antioxidant function.
Through molecular docking, the researchers revealed that these cyclic peptides might act by occupying the Kelch domain of Keap1, interfering with its interaction with the transcription factor Nrf2, thereby activating downstream antioxidant gene networks. This mechanistic insight not only confirms the activity of the cyclic peptides but also enhances their value as lead compounds, laying a solid foundation for subsequent medicinal chemistry optimization.
The study by Liu Hongcheng and colleagues demonstrates a particularly efficient pathway for discovering active cyclic peptides. However, translating these discoveries into deeper preclinical research and eventual drug development often presents researchers with an entirely new set of much more truly complex challenges.
During the synthesis of cyclic peptides, whether by chemical synthesis or enzymatic cyclization, various impurities can arise. These include uncyclized linear precursors, cyclization by-products such as dimers and oligomers, deletion sequences, and epimers. Such impurities can severely interfere with efficacy evaluations and toxicological results.
The small-scale separation methods used in the literature, for example silica gel columns, are highly effective for obtaining milligram quantities for identification. However, preparing gram or kilogram quantities of candidates for subsequent studies requires more robust, controllable, and scalable purification processes.
Confirming molecular weight solely by mass spectrometry is insufficient for cyclic peptides. Early candidates need more comprehensive analytical characterization, including confirmation of cyclization sites, assessment of conformational consistency, and establishment of impurity profiles to ensure batch-to-batch consistency and product quality.
Beyond activity, a newly discovered cyclic peptide's potential as a drug depends on properties such as permeability, metabolic stability, and solubility – its developability. The absence of early assessment for these attributes can lead to late-stage failures and significant waste of resources.
Addressing the challenges above – transforming an interesting cyclic peptide molecule into a qualified preclinical candidate – requires an integrated professional strategy encompassing design, optimization, synthesis, purification, and characterization. Creative Peptides services are designed precisely for this purpose, helping research teams move from discovery to development.
| Services | Contents |
| Our Cyclic Peptide Design and Optimization Services | Creative Peptides is more than just a synthesis provider; we partner with you from the early discovery phase. Our Cyclic Peptide Design and Optimization Services help you systematically refine active sequences – whether from literature or internal programs – into lead compounds with enhanced drug-like properties. Our expert team provides professional advice and execution on:
|
| Our Purification Strategies and Characterization Solutions – Precisely Addressing Complex Impurities | As noted in the literature, the impurity profile of cyclic peptides is far more complex than that of linear peptides. Our Purification Strategies and Analytical Characterization Services are specifically designed for this challenge. We provide:
|
| Our Developability Assessment and CMC Readiness | Advancing cyclic peptides into preclinical research requires early understanding of their developability – properties such as permeability, metabolic stability, and solubility. Our services cover the full spectrum from lead optimization to preclinical CMC readiness:
|
The corn gluten meal study proves that integrating bioinformatics, chemistry, and biology can uncover valuable antioxidant cyclic peptides. But translating such breakthroughs into real-world drugs or functional foods demands more than academic insight—it calls for a strategic, end-to-end development partner who understands the nuances of peptide therapeutics.
At Creative Peptides, we deliver exactly that. From design and synthesis to optimization and analytical characterization, we help biotech and pharma teams navigate the unique complexities of cyclic peptides. Whether you are dealing with tricky impurity profiles, low cyclization yields, or uncertain scalability, we provide practical solutions tailored to your program. We don't just aim for high affinity—we balance selectivity, permeability, stability, and manufacturability to get you to a viable candidate ready for further testing.
Take the next step today. Contact our scientific team for a customized solution. Let's work together to turn your cyclic peptide discoveries into life-changing medicines. Your molecule, our expertise—let's make it happen.
References
